"The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma"

PHASE2CompletedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions
Metastatic Renal Cell Carcinoma
Interventions
DRUG

HD IL2

Trial Locations (1)

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

City of Hope National Medical Center

OTHER

collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

collaborator

Dartmouth-Hitchcock Medical Center

OTHER

collaborator

Indiana University

OTHER

collaborator

Loyola University

OTHER

collaborator

Our Lady of Mercy Medical Center

OTHER

collaborator

Roswell Park Cancer Institute

OTHER

collaborator

University of California, Los Angeles

OTHER

collaborator

University of Cincinnati

OTHER

collaborator

University of Pittsburgh

OTHER

collaborator

University of Virginia

OTHER

collaborator

Vanderbilt University

OTHER

collaborator

Wayne State University

OTHER

collaborator

Dana-Farber Cancer Institute

OTHER

lead

Beth Israel Deaconess Medical Center

OTHER

NCT00554515 - "The High-Dose Aldesleukin (IL-2) Select Trial for Patients With Metastatic Renal Cell Carcinoma" | Biotech Hunter | Biotech Hunter